Get the Stockscreener App
0.6436
4.67%
0.0287
After Hours:
.66
0.0164
+2.55%
Scilex Holding Company stock is traded at $0.6436, with a volume of 671.65K.
It is up +4.67% in the last 24 hours and down -35.32% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$0.6149
Open:
$0.6405
24h Volume:
671.65K
Relative Volume:
0.35
Market Cap:
$86.19M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-1.0705
EPS:
-0.6012
Net Cash Flow:
$-21.04M
1W Performance:
+23.58%
1M Performance:
-35.32%
6M Performance:
-43.54%
1Y Performance:
-54.03%
1-Day Range:
$0.626
$0.67
1-Week Range:
$0.54
$0.6879
52-Week Range:
$0.4559
$2.63
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
0.6436 | 86.19M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
795.35 | 755.90B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
106.80 | 474.49B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
155.01 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.93 | 323.26B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
101.64 | 257.11B | 63.17B | 12.15B | 14.84B | 4.77 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
Scilex Holding Company Stock (SCLX) Latest News
Short Interest in Scilex Holding (NASDAQ:SCLX) Decreases By 51.1% - MarketBeat
Scilex Holding Co reaches agreement to waive default penalties By Investing.com - Investing.com South Africa
Scilex receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Scilex Holding Co reaches agreement to waive default penalties - Investing.com
Scilex receives Nasdaq non-compliance notice - Investing.com India
Scilex Holding Company Announces Receipt of Notice from Nasdaq - The Manila Times
Scilex Holding Company Announces Receipt of Notice from Nasdaq - GlobeNewswire Inc.
Sciatica Market Report 2032, DelveInsight | Sciatica Therapies & Companies, Clinical trials, Sciatica Treatment | Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kol - The Globe and Mail
Open Text Corp (OTEX-Q) QuotePress Release - The Globe and Mail
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 1419, 2024 - The Manila Times
Scilex Holding Company Announces Presentation of Data at - GlobeNewswire
Scilex Holding Company Announces Presentation of Data at the 2024 American College of ... - The Bakersfield Californian
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024 - Yahoo Finance
Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - Simply Wall St
Scilex shares face delisting risk on Nasdaq - Investing.com India
Scilex shares face delisting risk on Nasdaq By Investing.com - Investing.com UK
Scilex Holding Plans Merger to Boost Semnur Value - TipRanks
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Pre - The Manila Times
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of - GlobeNewswire
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces - The Bakersfield Californian
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - Barchart
Boeing Company (BA-N) QuotePress Release - The Globe and Mail
Chipotle Mexican Grill (CMG-N) QuotePress Release - The Globe and Mail
Scilex Pharmaceuticals announces end of phase II meeting with FDA for SP-103 - MSN
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Scilex executive chairperson Ji Henry buys $8,351 in stock - Investing.com
Scilex holding's CEO Jaisim Shah buys $31,670 worth of shares - Investing.com India
A W Food Services of Canada Inc (AW-T) QuotePress Release - The Globe and Mail
Pleasing Signs As A Number Of Insiders Buy Scilex Holding Stock - Yahoo Finance
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, - The Manila Times
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of - GlobeNewswire
Scilex holding's CEO Jaisim Shah buys $31,670 worth of shares By Investing.com - Investing.com Canada
Jaisim Shah Acquires 32,000 Shares of Scilex Holding (NASDAQ:SCLX) Stock - MarketBeat
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - ForexTV.com
Scilex Holding Company, Following its Prior Announcement of - GlobeNewswire
Scilex Holding Sets Dividend for Preferred Stock Exchange - TipRanks
Scilex Holding Company sets November 7, 2024 as the Record - GlobeNewswire
H.C. Wainwright maintains Buy on SCLX shares, cites notes offering - Investing.com
Alliance Global Partners Begins Coverage on Scilex (NASDAQ:SCLX) - Defense World
Scilex gains on spinoff plans for pharma subsidiary - MSN
Scilex director Followwill Dorman buys $990 in common stock By Investing.com - Investing.com South Africa
Scilex director Followwill Dorman buys $990 in common stock - Investing.com
Scilex director Chun Jay acquires $4,750 in common stock - Investing.com
Holding Company Shares Rally Following Board Of Directors Commentary - MSN
Scilex Holding (NASDAQ:SCLX) Director Yue Alexander Wu Acquires 20,000 Shares - MarketBeat
Scilex holding's executive chairperson Ji Henry buys $9,710 in stock - Investing.com
Scilex director Wu Yue Alexander buys $18,992 in common stock By Investing.com - Investing.com South Africa
Scilex director Wu Yue Alexander buys $18,992 in common stock - Investing.com India
Scilex holding's executive chairperson Ji Henry buys $9,710 in stock By Investing.com - Investing.com UK
Scilex director Chun Jay acquires $4,750 in common stock By Investing.com - Investing.com Australia
Scilex CFO Stephen Hoi purchases $6,499 in common stock - Investing.com India
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):